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A Ab bs st tr ra ac ct t
The NOD2 gene has been associated with susceptibility to Crohn’s disease and individuals with Crohn’s disease
are at increased risk for cancer at a number of organ sites. We studied the association between the 3020insC
allele of the NOD2 gene and cancer among 2604 cancer patients and 1910 controls from Poland. Patients
were diagnosed with one of twelve types of cancer in the Szczecin region between 1994 and 2004. Significant
associations were found for colon cancer (OR=1.8; 95% CI 1.2 to 2.6), for lung cancer (OR=1.7; 95% CI=1.1
to 2.5) and for ovarian cancer (OR=1.6; 95% CI 1.1 to 2.3). In addition, a significant association was found
for early-onset laryngeal cancer (OR=2.9; 95% CI 1.4 to 6.2) and for breast cancer in the presence of DCIS
(OR=2.1 95% CI=1.2 to 3.6). The NOD2 3020insC allele is relatively common (in Poland 7.3% of individuals)
and may be responsible for an important fraction of cancer cases. We estimate that the lifetime cancer risk
among carriers of this allele is 30% higher than that of individuals with two wild-type alleles. 
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I In nt tr ro od du uc ct ti io on n
There is a longstanding interest in the role of
chronic inflammation in carcinogenesis. Patients with
chronic gastritis, hepatic cirrhosis and pancreatitis are
at increased risk of cancer, and chronic gallstones and
schistosomiasis are risk factors for cancer of the
gallbladder and bladder respectively [1]. There is also
an elevated risk of colon cancer in individuals with
inflammatory bowel disease, including Crohn’s disease
and ulcerative colitis [2]. Epidemiologic evidence
supports a role of genetic factors in inflammatory bowel
disease and Crohn’s disease has been associated with
a mutation  in  the  gene  encoding  nucleotide
oligomerisation domain 2 (NOD2, also known as
CARD15) [3, 4]. This protein is a component of the
host defence against intracellular pathogens and is
expressed by monocytes, granulocytes and several
epithelial cells [5, 6]. Stimulation of NOD2-transfected
cell lines with bacterial protein results in the activation
of the nuclear factor κB (NFκB) pathway and deletion
of NOD2 leads to the enhanced NF-κB activity [6].
Approximately 25% of cases of Crohn’s disease carry
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3020insC, leads to the introduction of a stop codon
in exon 11 and generates a truncated NOD2 protein
which is missing the last 33 amino acids [3]. This
variant is associated with an increase in NF-κB activity
[6]. The other reported mutations are single amino acid
substitutions and the effect of these on the NOD2
protein function is less clear. 
Because of the reported associations between
NOD2 and Crohn’s disease and between Crohn’s
disease and colon cancer, we looked for NOD2
mutations in a series of 556 colon cancer patients from
Szczecin,  Poland  and  a positive  association  was
reported [7]. In order to define the range of cancer
phenotypes associated with the NOD2 3020insC
mutation we extended this study to include a total of
2604 invasive cancers of 12 different types and 1910
controls from Poland. 
M Me et th ho od ds s
Cancer  cases  were  collected  from  four  large
hospitals in the Szczecin area (University Clinic Hospitals,
Regional Oncology Hospital and Hospital for Lung
Diseases) between 1999 and 2004. Participation was
requested of study subjects during outpatient clinic visits
to the surgical and medical oncology clinics. In general,
patient participation rates exceed 90% for each cancer
site. Patients were consecutive, newly diagnosed cancer
cases, unselected for age, sex or family history. Because
of the relatively small number of patients with pancreatic
cancer in the oncology clinics (n=58) the pancreatic
cancer group was supplemented by the inclusion of 69
deceased patients for whom archived tumour material
was stored in the Pathology Department of the University
Clinic Hospital. The thyroid cancers were all of the
papillary type. 
Cancers  were  classified  according  to  age  of
diagnosis (<50 or ≥50). Because preliminary analyses
suggested the excess of invasive breast tumours with an
in  situ component  among  cases  with  the  NOD2
mutation, breast cancers were subdivided into subgroups
according to the presence or absence of DCIS. 
Two control groups were used. The first group
consisted of 910 newborn children from six hospitals
throughout Poland (Szczecin, Bia³ystok, Gorzów Wlkp.,
Katowice and Wroc³aw), all collected in 2003. The
second control group was taken from patient rolls of
three family doctors practicing in the Szczecin region.
Controls were selected at random from the patient lists
of these doctors. 
DNA  was  extracted  from  peripheral  blood
lymphocytes for all cases and controls with the exception
of 69 pancreatic patients whose DNA was obtained
from paraffin-embedded tumour tissue. The presence
of 3020insC was detected using the method of Ogura
et al [3] which is based on an allele-specific PCR assay.
Allele specific primers are used to generate fragments
of 319bp and 214bp representing the wild-type and
mutant alleles, respectively. To verify the accuracy of the
test a series of 29 samples was sequenced (11 positives
and  18  negatives)  and  these  were  completely
concordant  with  the  results  of  the  PCR  assay.
Additionally  the  presence  of  mutant  alleles  was
confirmed by sequencing or/and RFLP-PCR method
which uses the ApaI restriction enzyme. 
Statistical analysis included the comparison of the
proportions of the prevalence of the allele in cases and
controls. Odds ratios were generated from two-by-two
tables and statistical significance was assessed using
the (two-sided) Fisher exact test. Odds ratios were also
generated by patient subgroups defined by age of
diagnosis, and in the case of breast cancer, by the
presence of DCIS. 
R Re es su ul lt ts s
The NOD2 3020insC allele was found in 7.3% of
individuals  in  the  Polish  control  population.  The
prevalence of the NOD2 allele was higher in cancer
cases than in controls for eight of the twelve sites studied
(Table 1). The excess was statistically significant at the
p=0.05 level for cancers of the colon, lung and ovary.
Odds ratios were generated for all cancers (Table 1)
and by age of onset (<50, ≥50) (data not shown). The
association with colon cancer was strong for cancers
diagnosed above the age of 50 (OR=2.2; p=0.0006);
however the number of patients with colon cancer
diagnosed under the age of 50 was small (n=46). In
contrast, the effect of the 3020insC allele was only
restricted to laryngeal cancers diagnosed under the age
of  50  (OR=2.9;  p=0.009).  The  allele  did  not
predispose to breast cancer in the group as a whole,
but was seen much more commonly in cases with an
intraductal component (18 of 126; 14.3%) than in other
subtypes (19 of 336; 5.7%) (p=0.004 for difference).
The odds ratio for breast cancer with DCIS was 2.1
(p=0.01). The association was particularly strong for
breast cancers with DCIS in women diagnosed under
the age of 50 (OR 3.0; p=0.01). For one site (kidney)
significantly fewer cases were found to carry the NOD2
allele than expected (OR=0.4; p=0.03). 
D Di is sc cu us ss si io on n
Our data suggest that, in addition to Crohn’s
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T Ta ab bl le e   1 1. .   Association of the NOD2 3020insC mutation and selected types of cancer
S Si it te e N Nu um mb be er r   t te es st te ed d    N Nu um mb be er r   p po os si it ti iv ve e    P Pr re ev va al le en nc ce e   o of f   3 30 02 20 0i in ns sC C   ( (% %) ) O Od dd ds s   r ra at ti io o p p- -v va al lu ue e
b bl la ad dd de er r 172 18 10.5 1.5 0.13
b br re ea as st t 462 37 8.0 1.1 0.62 
with DCIS 126 18 14.3 2.1 0.009
without DCIS  336 19 5.7 0.76 0.30
c co ol lo on n 255  31  12.2  1.8 0.01
k ki id dn ne ey y 245 8 3.2 0.4 0.02
l la ar ry yn nx x 223  23 10.3 1.5 0.11
l lu un ng g 258  30 11.6 1.7 0.03
m me el la an no om ma a 198 10 5.1 0.7 0.31
o ov va ar ry y 317 35 11.0 1.6 0.03
p pa an nc cr re ea as s 127 6 4.7 0.6 0.37
p pr ro os st ta at te e 298  17 5.7 0.76 0.40
s st to om ma ac ch h 213  20 9.4 1.3 0.27
t th hy yr ro oi id d 82 8 9.8 1.4 0.39
controls 1910 140  7.3
gene leads to an increased susceptibility to a range of
solid tumours. It is likely that cancer is a much more
frequent manifestation of the NOD2 mutation than
Crohn’s disease. Based on the prevalence of 100 to
200 per 100,000 individuals for Crohn’s disease and
a relative risk of 2.6 associated with the NOD2
mutation  [4],  we  expect  that  fewer  than  1%  of
individuals with the NOD2 mutation will manifest
Crohn’s disease. In contrast, because of the elevated
risks for a wide range of common cancers seen, the
lifetime risk of cancer in carrier individuals will be many
times higher. Our study subjects included patients with
cancer of seven of the ten most common types of
cancer in Poland, and which represent about two-thirds
of all incident cases in the country [8]. The risks in Table
1 correspond to an overall increase of approximately
30% for the lifetime cancer risk for carriers of the
NOD2 3020insC allele mutation in Poland. 
Interestingly, several of the cancer sites for which an
association was seen are those which have previously
been reported to be in excess in patients with Crohn’s
disease – including the colon and lung [9-16]. In a study
from Italy three of the ten deaths in patients with Crohn’s
disease were due to lung cancer [17]. In addition,
patients with Crohn’s disease also have an increased
risk for inflammatory lesions of the larynx and for ovarian
granulomas and cysts [18-20]. Other sites of interest,
which appear to be in excess in Crohn’s disease, but
which were not studied here include lymphomas and
cancers of the gallbladder, small intestine and appendix
[9, 11, 21]. Overall, patients with Crohn’s disease have
a 29% increase in the risk of cancer [11]. It will be of
interest to establish the extent to which the NOD2 gene
is responsible for the malignant complications of Crohn’s
disease. Overall, 25% of patients with Crohn’s disease
in Western Europe carry the 3020insC allele. We expect
that the frequency of this allele in patients with Crohn’s
disease and malignancy might be much higher and that
the lifetime risk of cancer in this genetically-defined
subgroup will be increased. 
There was no clear relationship between age of onset
and the strength of the association. For laryngeal cancer
the association was stronger with young-onset cases, for
colon cancer the mutation was more prevalent in older-
onset cases, for the ovary cancer there was no clear age
effect. Typically, individuals with Crohn’s disease are at
increased risk for early-onset colon cancer. 
It is perhaps surprising that a single polymorphism
of the NOD2 gene has been associated with both
Crohn’s disease and with cancers of several sites,
including colon cancer, given that a familial association
of these two conditions has not been described. However,
it should be remembered that the lifetime penetrance ofH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(2) 62
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the allele for Crohn’s disease is probably less than 1%
and for colon cancer probably does not exceed 10%.
Therefore we do not expect that this allele, when present
in a population, will result in the generation of families
with a clear predisposition to the two conditions. 
Deletion of NOD2 leads to the increased activation
of NFκB [6]. NFκB activity is pro-inflammatory in the
gastro-intestinal tract as well as reducing apoptosis [22].
Patients with Crohn’s disease also have increased levels
of NF-κB activity. NF-κB also plays a role in chronic lung
disease and cigarette smoking is associated with both
increased NF-κB activity and lung cancer risk [23]. We
found the NOD2 mutation to confer an increased risk
of lung cancer; it is tempting to speculate that the NOD2
mutation leads to an increased risk of chronic obstructive
lung disease and to a greater lung cancer risk, but it
may be that other functions of NOD2, are equally or more
important. Cytokines that are upregulated by NF-κB
contribute to the growth of ovarian cancer tumour cells
[24] and inhibition of NF-κB activity in ovarian cancer
cells can suppress their growth [25]. 
Cases were recruited from the Szczecin region,
which is populated by ethnic Poles who immigrated to
the region from throughout Poland after the Second
World War, when German residents were relocated
elsewhere. Our control group was drawn both from
the adult population of Szczecin and from newborns
in five Polish cities. However, the frequency of the
3020insC allele was similar in the newborns (7.8%)
and in the adult population (6.9%) and there was no
statistical difference in the mutant allele frequency in
the newborns recruited from the Szczecin metropolitan
region (8.2%) or from other Polish cities (7.3%). It is
possible that there are minor differences in the ethnic
distribution of our cases and controls, but more
importantly, our association study benefits from the
general homogeneity of the Polish population, which
is much less ethnically diverse than the populations of
North America or of most Western European countries.
This ethnic homogeneity has been exploited in several
genetic studies in the past [26, 27]. This allele is
present in other European countries and we expect that
our findings will be replicated elsewhere, as they have
been for colorectal cancer in the Greek population
[28]. There may be exceptions in some populations –
for instance NOD2 polymorphisms could not be
confirmed in the Finnish population as reported by
Aaltonen et al [29] but we believe that this is most likely
an exception and not the rule. 
We have previously reported that the NOD2 gene
is associated with an increased risk of colon cancer, in
particular for patients diagnosed above the age of 50
years. We now believe that the gene is responsible for
a wide range of cancer types, including lung, larynx and
ovary. However, multiple comparisons were made and
it is possible that some of our findings are due to chance.
It will be important to confirm these findings in other
populations. We believe that the presence of the NOD2
3020insC allele increases the lifetime risk of cancer by
approximately 25% to 35%. For no single site was the
increase particularly dramatic and at this point no
standards of clinical recommendations regarding genetic
screening or clinical surveillance can be made. NOD2
is involved in the regulation of the inflammatory process,
but it is not clear that impairment in inflammation is the
mechanism underlying the increased risk of cancer
described here. It will be of interest to see if other genes
involved in inflammation, or which are associated with
inflammatory  bowel  disease,  such  as  the  recently
described OCTN cation transporter genes [30], are also
found to be associated with cancer susceptibility. 
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